MM_Hub: CONGRESS|#EHA2021| @ninashah33 presented about novel immunotherapies including CAR-T, ADCs, bispecific. It was emphasized that bringing novel therapies to 1st line will bring complications. #mmsm #myeloma @UCSFMedicine

by | Jun 14, 2021 | Twitter

CONGRESS|#EHA2021| @ninashah33 presented about novel immunotherapies including CAR-T, ADCs, bispecific. It was emphasized that bringing novel therapies to 1st line will bring complications. #mmsm #myeloma @UCSFMedicine pic.twitter.com/d846109i7Y— Multiple Myeloma Hub...

MM_Hub: CONGRESS|#EHA2021|Maria Mateos, University of Salamanca, immune based approaches can improve disease control over time. moAB targeting CD-38 e.g. Dara & Dara-Rd has improved the outcomes. CAR-T cell incorporation in 1st line of therapy was also discussed #mmsm #myeloma

by | Jun 14, 2021 | Twitter

CONGRESS|#EHA2021|Maria Mateos, University of Salamanca, immune based approaches can improve disease control over time. moAB targeting CD-38 e.g. Dara & Dara-Rd has improved the outcomes. CAR-T cell incorporation in 1st line of therapy was also discussed #mmsm...

MM_Hub: CONGRESS|#EHA2021|Francesca Gay, University of Torino highlighted the need for comprehensive baseline evaluation of prognostic factors. Approved therapies with suboptimal efficacy are available but there is a need for a new approach. MRD driven therapies are needed #mmsm #myeloma

by | Jun 14, 2021 | Twitter

CONGRESS|#EHA2021|Francesca Gay, University of Torino highlighted the need for comprehensive baseline evaluation of prognostic factors. Approved therapies with suboptimal efficacy are available but there is a need for a new approach. MRD driven therapies are needed...

MM_Hub: CONGRESS|#EHA2021|@MyMKaiser, Institute of Cancer Research highlighted myeloma molecular risk in the era of modern agents. Use of validated risk markers and quantitative molecular risk assessment is important to identify unmet needs of pts at diagnosis. #mmsm, #myeloma

by | Jun 14, 2021 | Twitter

CONGRESS|#EHA2021|@MyMKaiser, Institute of Cancer Research highlighted myeloma molecular risk in the era of modern agents. Use of validated risk markers and quantitative molecular risk assessment is important to identify unmet needs of pts at diagnosis. #mmsm,...

MM_Hub: CONGRESS|#EHA2021|@RobertoMinaMD, European Myeloma Network presented results for FORTE trial. Carfilzomib-lenalidomide-dexamethasone induction/consolidation with ASCT (KRd_ASCT) had improved PFS. Effective KR maintenance in pts with 1 yr-MRD negative rates obtained #mmsm #myeloma

by | Jun 14, 2021 | Twitter

CONGRESS|#EHA2021|@RobertoMinaMD, European Myeloma Network presented results for FORTE trial. Carfilzomib-lenalidomide-dexamethasone induction/consolidation with ASCT (KRd_ASCT) had improved PFS. Effective KR maintenance in pts with 1 yr-MRD negative rates obtained...